Latest filing published 15 May 2025 for 2seventy bio, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Filings by William D. Baird III span 3 companies, the busiest being 2seventy bio, Inc., Amicus Therapeutics, Inc. and bluebird bio, Inc. Over a trading history stretching from 4 January 2016 to 13 May 2025, the count stands at 26 filings.
Every open-market trade on record is a sale: 14 sales worth €510k. Other entries cover 9 share grants and 1 option exercise. 2025 to date brings no purchases and 3 sales.
The newest entry dates from 15 May 2025: a transaction, in 2seventy bio, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 26 declarations